Evidence map›Paper›PMID 38782945›Full record

ArticleScientific reports2024

Author Correction: Development of a novel UHPLC-MS/MS-based platform to quantify amines, amino acids and methylarginines for applications in human disease phenotyping.

Blerina Ahmetaj-Shala, Michael Olanipekun, Abel Tesfai, Niall MacCallum, Nicholas S Kirkby, Gregory J Quinlan, Chih-Chin Shih, Ryota Kawai, Sharon Mumby, Mark Paul-Clark and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Blerina Ahmetaj-Shala *Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK. b.ahmetaj@imperial.ac.uk.
Michael Olanipekun *Department of Surgery and Cancer, Imperial College London, London, SW7 2BB, UK.ORCID http://orcid.org/0000-0001-7844-0370
Abel Tesfai *Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK.
Niall MacCallumCritical Care, University College London Hospital, London, NW1 2BU, UK.
Nicholas S KirkbyCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK.
Gregory J QuinlanCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK.
Chih-Chin ShihCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK.
Ryota KawaiCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK.
Sharon MumbyRespiratory, Airway Disease, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK.
Mark Paul-ClarkCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK.
Elizabeth J WantDepartment of Surgery and Cancer, Imperial College London, London, SW7 2BB, UK. e.want@imperial.ac.uk.
Jane A MitchellCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, SW3 6LY, UK. j.a.mitchell@ic.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38782945
PMCPMC11116535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.